A deeper look into endoscopyJune 4, 2018One of the first things veterinarians learn in school about endoscopes is how gastrointestinal endoscopy (GI) can be used to aid in the diagnostic evaluation of clinical signs referable to the esophagus, stomach, as well as proximal small intestine.
SPONSORED CONTENTHow can you help new pet owners keep their new dogs protected?See why new dog owners and their pets can benefit from simple triple protection in one monthly chew. + See the Difference
Zomedica announces therapeutic development milestonesDecember 13, 2017Zomedica Pharmaceuticals Corp. veterinary pharmaceutical and diagnostic company announced a development update on the company's four therapeutic candidates for use in companion animals, namely dogs and cats. ZM-012 and ZM-007: Metronidazole for acute diarrhea in dogs Development milestones for ZM-012 and ZM-007, complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs include: Finalized novel tablet formulation for ZM-012 to replace the large, bitter tasting human-approved generic tablet commonly prescribed by veterinarians for their canine patients. The beef-flavored oral tablets are intended for dogs greater than 9 pounds or 4 kilograms. Finalized the oral suspension formulation for ZM-007, which is intended for small breeds and puppies under 9 pounds or 4 kilograms. Completed pilot testing for both formulations at Michigan State University College of Veterinary Medicine to measure metronidazole's effectiveness to treat acute diarrhea in dogs. Scheduled December 2017 pre-submission meeting with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) to present the regulatory strategy and development plan for ZM-012. A safety study will commence for ZM-012 in the first half of 2018 for completion in the second half of 2018. The company also expects to hold a pre-submission …
Zomedica banks on canine diarrhea drugsDecember 19, 2016Zomedica Pharmaceuticals Corp. has started talks with the U.S. Food and Drug Administration on the company’s third proposed veterinary product: an oral suspension formulated for the treatment of canine diarrhea.
